Spero Therapeutics, Inc. Common Stock
SPRO Real Time Price USDRecent trades of SPRO by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by SPRO's directors and management
Government lobbying spending instances
-
$20,000 Jul 17, 2022 Issue: Health Issues
-
$50,000 Apr 17, 2022 Issue: Health Issues
-
$50,000 Jan 17, 2022 Issue: Health Issues
Estimated quarterly lobbying spending
New patents grants
-
Patent Title: Tebipenem pivoxil crystalline forms, compositions including the same, methods of manufacture, and methods of use Sep. 24, 2024
-
Patent Title: High dosage tebipenem pivoxil tablet formulation Jul. 30, 2024
-
Patent Title: Tebipenem pivoxil crystalline forms, compositions including the same, methods of manufacture, and methods of use Aug. 08, 2023
-
Patent Title: Polymyxin compounds Oct. 04, 2022
-
Patent Title: Tebipenem pivoxil crystalline forms, compositions including the same, methods of manufacture, and methods of use Jan. 12, 2021
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Number of mentions of SPRO in WallStreetBets Daily Discussion
Recent insights relating to SPRO
Recent picks made for SPRO stock on CNBC
ETFs with the largest estimated holdings in SPRO
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view SPRO Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.